BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026.
World J Gastroenterol. Nov 21, 2026; 32(43): 121310
Published online Nov 21, 2026. doi: 10.3748/wjg.121310
Table 1 Stage-specific operational framework for neutrophil-hepatic stellate cells crosstalk and therapeutic posture
Stage
Clinical/histological window
Dominant cellular-molecular signature
Neutrophil functional output
Therapeutic posture
I Acute injury (hours-days)ALT/AST ↑↑, no fibrosisLy6Ghi infiltration peak; transient MPO-DNA/cit-H3↑; early αSMA inductionDual: Early cytotoxic; late reparativeSelective: PAD4 inhibition + NLRP3 dampening in early window; preserve late reparative phenotype
II Chronic active fibrosis (months-years)NLR ↑, FibroScan ≥ 8.5 kPa or ELF ≥ 9.8, F2-F3Sustained MPO-DNA/cit-H3 ↑; CCL2, CXCL10 ↑; persistent NETs-HSCs loopSelf-amplifying pro-fibroticDisrupt loop: COX-2 + NLRP3 + TGFβR1; avoid prolonged NETs ablation
III Cirrhosis/HCC (F4+ tumor)High NLR, PIVKA-II/AFP ↑PD-L1+/PLAUR+ TANs; NETs-rich immune-excluded nichePro-tumor, immunosuppressiveCombination: PAD4 or NLRP3 + TGFβR1 + ICI; close infection monitoring


Write to the Help Desk